Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00246402 · ClinicalTrials.gov registry record · NA
Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV
A NA study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT00246402 is a NA study that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 30 participants.
The verdict
NCT00246402, a NA study, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to test whether chronic administration of the drug acipimox will improve hyperlipidemia and insulin sensitivity among HIV infected patients experiencing highly active antiretroviral therapy (HAART) associated metabolic disturbances.
Interventions
- DRUG Acipimox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2002-09 |
| Est. Completion | 2006-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00246402
The ClinicalTrials.gov registry entry for NCT00246402 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Acipimox is the first listed.
NCT00246402 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00246402 about?
NCT00246402 is a clinical study titled "Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV". The purpose of this study is to test whether chronic administration of the drug acipimox will improve hyperlipidemia and insulin sensitivity among HIV infected patients experiencing highly active antiretroviral therapy (HAART) associated metabolic disturbances.
What is the current status of trial NCT00246402?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2002-09. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00246402?
The interventions under investigation include: Acipimox (DRUG).
Who is sponsoring clinical trial NCT00246402?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.